Linyan Medical Secures New Funding Round Led by Huayi Capital to Co-Build an AR and AI-Powered Digital Orthopedic Ecosystem
LINYAN
Orthopedic Surgical Robot R&D and Manufacturer
VCBeat has learned that Shanghai LINYAN Medical Technology Co., Ltd. (hereinafter referred to as “LINYAN”) has successfully completed a new round of financing, with Huayi Capital—a firm specializing in quantitative evaluation and investment in the primary market for healthcare and wellness—as the investor. Following this round, LINYAN will accelerate the commercialization of its AR-guided navigation system for spinal surgery and intensify R&D and product deployment in AI-driven, digitally intelligent orthopedics, aiming to provide doctors, hospitals, and the broader medical market with more efficient, safer, and cost-effective innovative solutions.
LINYAN is a company dedicated to the research, development, and application of clinical surgical assistance equipment. Since 2017, the company has been committed to developing surgical navigation systems. With the primary goals of enhancing surgeons’ visual capabilities, freeing their hands, reducing reliance on experience-based procedures, and lowering costs for both hospitals and patients, LINYAN deeply integrates metaverse, artificial intelligence, surgical navigation, and robotic technologies. This approach provides more precise, safe, and efficient navigation and positioning systems for the field of surgical operations.
The company holds nearly 90 patents and 7 software copyrights, spanning the fields of artificial intelligence, augmented reality, surgical navigation, and surgical robotics, demonstrating robust technical capabilities. Building on this foundation, the company has independently developed multi-source, multi-modal image registration tools, as well as guidance and interaction technologies within augmented reality environments, providing high-precision, user-friendly, and cost-effective comprehensive solutions for surgical procedures.
Currently, the company’s product portfolio covers spinal surgery and is gradually expanding into joint surgery, sports medicine, neurosurgery, pulmonology, and other fields. The company continues to deepen its “industry-academia-research-clinical” integrated collaboration with leading spinal surgery hospitals, including Shanghai General Hospital, Changzheng Hospital, Shanghai Sixth People’s Hospital, and the Chinese PLA General Hospital, as well as with universities and research institutions such as Shanghai Jiao Tong University, Southeast University, and the Shanghai Artificial Intelligence Laboratory.
LINYAN has received unanimous acclaim from physicians, hospitals, universities and research institutes, third-party evaluation agencies, and patients for the precision, reliability, accessibility, and cost-effectiveness of its products. The first-generation product, the Holonavi S Spinal Surgical Navigation System, has completed registration clinical trials and dossier review, and was approved by the National Medical Products Administration (NMPA) as a Class III active medical device on April 17, 2024.
It is worth mentioning that over the past year, in the face of numerous external uncertainties, LINYAN has forged ahead and achievedMultiple Milestone Breakthroughs:
In April, LINYAN’s Holonavi S, China’s first AR-based surgical navigation system for spine surgery independently developed by the company, received NMPA approval for market launch;
In May, LINYAN held a new product launch event at Shanghai General Hospital and jointly established China’s first training base for AR-guided spinal surgery navigation systems with the hospital; it also signed a cooperation agreement on the Orthopedic Digital Application Center project with the Orthopedic Medical Research Center of Dalian University.
In June, LINYAN participated in the 15th Annual Meeting of the Chinese Orthopaedic Association (CAOS 2024);
In October, LINYAN's AR surgical navigation system for spinal surgery received production approval;
In December, LINYAN participated in the 23rd Academic Conference of Orthopaedics of the Chinese Medical Association and the 16th COA Academic Congress, where its products created a sensation.
Recently, LINYAN has achieved another breakthrough, welcoming a new partner and family member—Huayi Capital.
Currently, the annual volume of spinal surgeries exceeds 1.7 million, while that of orthopedic surgeries surpasses 7 million, with a compound annual growth rate (CAGR) of over 18%. According to an analysis report by Merck & Co., it is projected that by 2030, the annual volume of spinal surgeries will reach 6 million, and orthopedic surgeries will exceed 20 million.
Despite the rapid growth in surgical volume, the number of orthopedic surgeons per 1,000 people remains below 5%. Under the traditional training model, it takes more than 10 years for most spine surgeons to reach proficiency, leading to a widening gap between supply and demand. In this context, digital and intelligent orthopedic clinical products can address critical pain points related to accessibility, efficiency, and safety, holding significant market potential. In reality, continuous advancements in medical technology are driving profound transformations in the field of orthopedics. As an emerging force in the industry, Shanghai LINYAN Medical Technology Co., Ltd. has always adhered to a physician-centric philosophy in the development of intelligent orthopedic clinical products. Leveraging its unique concepts and innovative technologies, LINYAN is making steady progress in this domain. With the conviction that “a time will come to ride the wind and cleave the waves, to set my cloud-white sail and cross the sea which raves,” LINYAN looks forward to collaborating with more outstanding partners to jointly build a digital and intelligent orthopedic ecosystem.
Regarding this round of financing, Huayi Capital stated“LINYAN has filled a market gap with China’s first AR surgical navigation system for spine surgery to receive NMPA certification, demonstrating robust technological innovation. Its product design closely aligns with clinical needs, adapting to lower-tier markets through cost reduction, while achieving precise market coverage via deep collaboration with China Resources Pharmaceutical. LINYAN’s innovation, commercialization strategy, and channel resource advantages confer significant competitiveness. We are optimistic about the company’s potential in promoting the adoption of precision medicine and advancing surgical navigation technologies, and believe it will continue to create greater value for the industry and investors.”
Huayi Capital is a representative institution focused on quantitative evaluation and investment in the primary market of the healthcare and wellness industry. It has filed nine funds with an assets under management (AUM) scale of nearly RMB 8 billion. As a research-driven investment firm, Huayi Capital houses China’s only medical investment research institute—the Huayi Research Institute—and serves as the definer of the panoramic landscape of medical investment in China. Yiyun Technology acts as Huayi’s post-investment management platform, dedicated to profiling and evaluating domestic healthcare and wellness enterprises using quantitative models.